Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Anti-SSA (Ro) Antibody

Immunology & Autoimmune

Anti-RoRo/SSA antibodySSA

Review status

Currently under review

Pending specialist review and validation.

What it shows

The Anti-SSA (Ro) test looks for specific autoantibodies in your blood that target proteins called Ro, which are part of the extractable nuclear antigen group. These antibodies are produced by your immune system and can be a clue that it is reacting against your own tissues.

This test is commonly performed along with an ANA and an ENA panel to help evaluate conditions such as Sjogren’s syndrome and lupus. Anti-SSA antibodies can also be seen in other autoimmune conditions, and occasionally in people without clear symptoms, so results are interpreted in clinical context.

Why it matters

Anti-SSA antibodies can help your clinician understand whether symptoms like dry eyes, dry mouth, skin rashes that worsen with sunlight, joint pain, or certain blood count changes could be related to an autoimmune condition. The result can guide further testing, referrals, and treatment planning.

During pregnancy, the presence of anti-SSA antibodies can be associated with risks to the baby, so your care team may recommend closer monitoring. The test can also help distinguish among different connective tissue diseases, influence medication choices, and signal when additional organ-focused evaluation is appropriate.

Understanding your results

A positive result supports the possibility of an autoimmune condition, but it is not a diagnosis by itself. Your clinician will consider your symptoms, examination, and other tests to decide what it means for you. A negative result lowers the likelihood of some conditions but does not rule them out, especially if your symptoms are strong or other tests are abnormal.

If your result is positive and you are pregnant or planning pregnancy, your care team may discuss medication review and monitoring for the baby. If results are borderline or unexpected, your clinician may repeat the test or use a different method. Follow-up may include additional ENA antibodies, complement levels, eye or salivary gland assessments, or imaging, depending on your situation.

Reference ranges

019 RU/mL
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Anti-SSA (Ro) Antibody

  • Assay and lab method differences

    Different laboratories use different test platforms, which can lead to small variations in results and cutoffs. If possible, try to use the same lab for follow-up testing so trends are easier to compare.

  • Biotin and supplement interference

    High intake of biotin in hair, skin, and nail supplements can interfere with some immunoassays and cause misleading results. Stop high-dose biotin for at least a full day before blood draw unless your clinician advises otherwise.

  • Medications and immune therapies

    Immunosuppressive drugs can lower measurable autoantibody levels over time, while intravenous immunoglobulin can cause transient positivity due to passive antibodies. Always tell the lab and your clinician about recent treatments.

  • Acute illness and inflammation

    Intercurrent infections or inflammatory flares can alter immune activity and sometimes affect autoantibody measurements or their interpretation. Testing when you are clinically stable can help with clarity.

  • Pregnancy considerations

    If you are pregnant or planning pregnancy and have anti-SSA antibodies, your care team may recommend specific monitoring strategies. Discuss timing of testing and follow-up early in prenatal care.

2026

References

  1. McGill University Health Centre. (2009, October 05). Anti-SSA (RO) (Task CD 699295). Laboratory reference ranges.
  2. Shiboski, C. H., Shiboski, S. C., Seror, R., Criswell, L. A., Labetoulle, M., Lietman, T. M., Rasmussen, A., Scofield, H., Vitali, C., Bowman, S. J., & Mariette, X. (2017). 2016 ACR/EULAR classification criteria for primary Sjogren’s syndrome: A consensus and data-driven methodology. Arthritis & Rheumatology, 69(1), 35–45. External link
  3. Sammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J. P., & et al. (2020). 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care & Research, 72(4), 461–488. External link